Found: 19
Select item for more details and to access through your institution.
P1‐046: BASELINE CHARACTERISTICS FROM CREAD2: A PHASE III TRIAL OF CRENEZUMAB IN EARLY (PRODROMAL‐TO‐MILD) ALZHEIMER'S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P250, doi. 10.1016/j.jalz.2019.06.071
- By:
- Publication type:
- Article
O1‐02‐04: BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER'S DISEASE (CREAD).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P217, doi. 10.1016/j.jalz.2018.06.2339
- By:
- Publication type:
- Article
MATHEMATICAL MODEL OF AMYLOID BETA (Aβ) DYNAMICS TO ASSESS TARGET ENGAGEMENT OF SOLUBLE Aβ OLIGOMERS BY CRENEZUMAB IN THE ALZHEIMER’S DISEASE BRAIN.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P282, doi. 10.1016/j.jalz.2017.06.176
- By:
- Publication type:
- Article
A PHASE I STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RO7105705 IN HEALTHY VOLUNTEERS AND PATIENTS WITH MILD-TO-MODERATE AD.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P601, doi. 10.1016/j.jalz.2017.07.243
- By:
- Publication type:
- Article
CLINICAL TRIAL DESIGN OF CREAD: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE 3 STUDY TO EVALUATE CRENEZUMAB TREATMENT IN PATIENTS WITH PRODROMAL-TO-MILD ALZHEIMER’S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P609, doi. 10.1016/j.jalz.2016.06.1207
- By:
- Publication type:
- Article
Injectable Polymer‐Nanoparticle Hydrogel for the Sustained Intravitreal Delivery of Bimatoprost.
- Published in:
- Advanced Therapeutics, 2023, v. 6, n. 2, p. 1, doi. 10.1002/adtp.202200207
- By:
- Publication type:
- Article
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
- Published in:
- JAMA Neurology, 2022, v. 79, n. 8, p. 758, doi. 10.1001/jamaneurol.2022.1375
- By:
- Publication type:
- Article
Evolutionary conservation of histone macroH2A subtypes and domains.
- Published in:
- Nucleic Acids Research, 1998, v. 26, n. 12, p. 2837, doi. 10.1093/nar/26.12.2837
- By:
- Publication type:
- Article
Assessment of Color Reproducibility and Mitigation of Color Variation in Whole Slide Image Scanners for Toxicologic Pathology.
- Published in:
- Toxicologic Pathology, 2023, v. 51, n. 6, p. 313, doi. 10.1177/01926233231224468
- By:
- Publication type:
- Article
Toxicologic Pathology Forum: A Roadmap for Building State-of-the-Art Digital Image Data Resources for Toxicologic Pathology in the Pharmaceutical Industry.
- Published in:
- Toxicologic Pathology, 2022, v. 50, n. 8, p. 942, doi. 10.1177/01926233221132747
- By:
- Publication type:
- Article
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits.
- Published in:
- Science Translational Medicine, 2020, v. 12, n. 540, p. 1, doi. 10.1126/scitranslmed.aav0820
- By:
- Publication type:
- Article
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.
- Published in:
- Science Translational Medicine, 2015, v. 7, n. 273, p. 1, doi. 10.1126/scitranslmed.aaa3634
- By:
- Publication type:
- Article
Translational Approaches for Brain Delivery of Biologics via Cerebrospinal Fluid.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 4, p. 826, doi. 10.1002/cpt.2531
- By:
- Publication type:
- Article
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 1, p. 62, doi. 10.1002/psp4.12876
- By:
- Publication type:
- Article
Widespread brain distribution and activity following i.c.v. infusion of anti-β-secretase (BACE1) in nonhuman primates.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier.
- Published in:
- Science Translational Medicine, 2013, v. 5, n. 183, p. 1, doi. 10.1126/scitranslmed.3005338
- By:
- Publication type:
- Article
An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.
- Published in:
- British Journal of Pharmacology, 2013, v. 168, n. 2, p. 445, doi. 10.1111/j.1476-5381.2012.02138.x
- By:
- Publication type:
- Article
The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell-surface-targeted biological agents in patients.
- Published in:
- British Journal of Pharmacology, 2012, v. 166, n. 5, p. 1600, doi. 10.1111/j.1476-5381.2012.01916.x
- By:
- Publication type:
- Article
Analysis of cellularity in H&E-stained rat bone marrow tissue via deep learning.
- Published in:
- Journal of Pathology Informatics, 2023, v. 14, p. 1, doi. 10.1016/j.jpi.2023.100333
- By:
- Publication type:
- Article